| VEMIX | VVIEX | VEMIX / VVIEX | |
| Total Expense Ratio | 0.09 | N/A | - |
| Annual Report Gross Expense Ratio | 0.09 | N/A | - |
| Fund Existence | 26 years | 3 years | - |
| Gain YTD | 21.721 | 33.109 | 66% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 5000000 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 141B | 532M | 26,504% |
| Annual Yield % from dividends | 2.82 | 1.50 | 187% |
| Returns for 1 year | 20.22 | 30.79 | 66% |
| Returns for 3 years | 46.12 | N/A | - |
| Returns for 5 years | 20.62 | N/A | - |
| Returns for 10 years | 89.03 | N/A | - |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IHE | 86.21 | 0.86 | +1.01% |
| iShares US Pharmaceuticals ETF | |||
| IWFL | 59.15 | 0.29 | +0.48% |
| ETRACS 2x Leveraged US Gr Fctr TR ETN | |||
| SCHF | 24.14 | 0.05 | +0.21% |
| Schwab International Equity ETF™ | |||
| FDTX | 41.24 | 0.08 | +0.19% |
| Fidelity Disruptive Technology ETF | |||
| XCNY | 27.98 | -0.05 | -0.19% |
| SPDR S&P Emerging Markets ex-China ETF | |||